Drugs / VS-7375
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07020221 | Jun 2025 → Dec 2028 expected | colorectal cancer, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma | Verastem, Inc. | Recruiting | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07659795 | Jul 2026 → Jun 2027 expected | colorectal cancer | Verastem, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT07644559 | Jun 2026 → Jun 2027 expected | pancreatic ductal adenocarcinoma | Verastem, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT07659782 | Jun 2026 → Jun 2027 expected | non-small cell lung carcinoma | Verastem, Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VS-7375 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07644559 ↗ |
| Action | Inhibit | “VS-7375 is a highly selective oral, non-covalent, small molecule KRAS G12D (ON/OFF) inhibitor.” NCT07020221 ↗ |
| Modality | Small molecule | “VS-7375 is a highly selective oral, non-covalent, small molecule KRAS G12D (ON/OFF) inhibitor.” NCT07020221 ↗ |
| Route | Oral | “VS-7375 is a highly selective oral, non-covalent, small molecule KRAS G12D (ON/OFF) inhibitor.” NCT07020221 ↗ |
| Target | KRAS | “VS-7375 is a highly selective oral, non-covalent, small molecule KRAS G12D (ON/OFF) inhibitor.” NCT07020221 ↗ |